Methylation of APC and GSTP1 in Non-Neoplastic Tissue Adjacent to Prostate Tumour and Mortality from Prostate Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Richiardi, Lorenzo ^a   Fiano, Valentina ^a   Grasso, Chiara ^a   Zugna, Daniela ^a   Delsedime, Luisa ^b   Gillio Tos, Anna ^a   Merletti, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; DNA; GLUTATHIONE TRANSFERASE P1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CARCINOGENESIS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HAZARD RATIO; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; NON NEOPLASTIC TISSUE; PROMOTER REGION; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; TISSUES;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84879968416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068162     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer. GLOBOCAN 2008 v1.2.
2. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, et al. (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155: 762-771.
3. Hegarty J, Beirne PV, Walsh E, Comber H, Fitzgerald T, et al. (2011) Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev CD006590.
4. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, et al. (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364: 1708-1717.
5. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, et al. (2009) Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 27: 3161-3168.
6. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, et al. (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 29: 2391-2396.
7. Seligson DB, Horvath S, Shi T, Yu H, Tze S, et al. (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266.
8. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, et al. (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60: 753-766.
9. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, et al. (2011) Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer 129: 2454-2462.
10. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, et al. (2007) High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 13: 6122-6129.
11. Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, et al. (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11: 8321-8325.
12. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, et al. (2008) CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 71: 161-167.
13. Banez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, et al. (2011) Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol 184: 149-56.
14. Weiss G, Cottrell S, Distler J, Schatz P, Kristiansen G, et al. (2009) DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol 181: 1678-1685.
15. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, et al. (2011) The Epigenetic promise for prostate cancer diagnosis. Prostate 72: 1248-1261.
16. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799.
17. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, et al. (2009) Differential gene expression in tumor adjacent histologically normal prostate tissue indicates field cancerization. Int J Oncol 35: 537-46.
18. Trevino V, Tadesse MG, Vannucci M, Al-Shahrour F, Antczak P, et al. (2011) Analysis of normal-tumour tissue interaction in tumours: prediction of prostate cancer features from the molecular profile of adjacent normal cells. PLoS ONE 6: e16492.
19. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, et al. (2005) Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 5: 45.
20. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, et al. (2011) Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res 16: 5414-5423.
21. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, et al. (2005) Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 173: 610-614.
22. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, (2006) al (2006) Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 8: 312-319.
23. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, et al. (2008) Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 68: 152-160.
24. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, et al. (2006) Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 98: 255-261.
25. Jentzmik F, Krause H, Reichelt U, Schrader AJ, Schrader M, et al. (2012) GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy. World J Urol 30: 541-546.
26. Pizzi C, De Stavola B, Merletti F, Bellocco R, Dos Santos Silva I, et al. (2011) Sample selection and validity of exposure-disease association estimates in cohort studies. J Epidemiol Community Health 65: 407-411.
27. Gillio-Tos A, De Marco L, Fiano V, Garcia-Bragado F, Dikshit R, et al. (2007) Efficient DNA extraction from 25-year-old paraffin-embedded tissues: study of 365 samples. Pathology 39: 345-348.
28. Esteller M. (2005) DNA methylation. Approaches, methods, and applications: Taylor and Frances e-Library.
29. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, et al. (2001) Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61: 3410-3418.
30. Woodson K, Hanson J, Tangrea J, (2004) A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett 205: 181-188.
31. Fine J, Gray RJ, (1999) A proportional hazards model for the subdistribution of a competing risk. JASA 94: 496-509.
32. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, et al. (2004) GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer J Cell Biochem. 91: 540-552.
33. Fearnhead NS, Britton MP, Bodmer WF, (2001) The ABC of APC. Hum Mol Genet 10: 721-733.
34. Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, et al. (2004) Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 91: 985-994.
35. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, et al. (2006) Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4: 1-8.